Related Experiment Video
Updated: Jul 14, 2026

In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase
Published on: April 4, 2025
Fulminant hepatic failure complicating visceral leishmaniasis in an apparently immunocompetent child
Arun K Baranwal1, Ravi N Mandal, Rupa Singh
1Postgraduate Institute of Medical Education & Research, Chandigarh, India. baranwal1970@yahoo.com
Insights
Fulminant hepatic failure (FHF), a rare complication of visceral leishmaniasis (VL), rapidly progressed to a fatal outcome in a young child. The case highlights the need for further research into immunomodulatory therapies for this severe presentation.
Area of Science:
- Parasitology
- Hepatology
- Immunology
Background:
- Visceral leishmaniasis (VL) is a severe systemic parasitic disease.
- Fulminant hepatic failure (FHF) is an exceptionally rare but potentially fatal complication of VL.
- Limited established guidelines exist for managing FHF in the context of VL.
Observation:
- A 1.5-year-old girl presented with visceral leishmaniasis.
- The patient rapidly developed progressive and ultimately fatal fulminant hepatic failure.
- The clinical course was characterized by rapid deterioration of liver function.
Findings:
- The case demonstrates a severe, rapidly progressive hepatic manifestation of VL.
- The etiology of FHF in this VL case warrants further investigation.
- Standard VL treatments may not be sufficient to prevent or manage this severe hepatic complication.
Implications:
- This case underscores the critical need for early recognition and aggressive management of VL-associated FHF.
- Further research into the pathophysiology of VL-induced FHF is crucial.
- The potential role and safety of adjunctive immunomodulatory therapies in managing VL-associated FHF require exploration.
Abstract:
Fulminant hepatic failure (FHF) is an unusual complication of visceralleishmaniasis (VL). Here, we present a 1.5-yr-old girl with VL developing rapidly progressive fatal FHF. In absence of established guidelines, additional use of immunomodulatory therapies has been discussed in reference to available information.
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Rocky Mountain Spotted Fever
Cryptococcal Meningitis
Amebiasis
